Request for Free Sample

Diabetic Nephropathy Market Size Analysis:

The Diabetic Nephropathy Market size was valued at USD 2.71 billion in 2024 and is expected to reach USD 3.97 billion by 2032, growing at a CAGR of 4.98% over the forecast period of 2025-2032.

The global diabetic nephropathy market is witnessing steady growth owing to rising diabetes prevalence globally, especially type 2 diabetes. Diabetic nephropathy market growth is fueled by rising awareness about the disease, an increasing number of early diagnoses, and the emergence of new therapies such as SGLT2 inhibitors. Growth is also encouraged with government initiatives, with people having better access to chronic kidney disease treatments. For instance, innovation is being spurred by rapid technological advancements and the inception of clinical trials focused on renal protection among these patients. Across all developed and developing economies, steady growth for the market is forecasted until 2032.

The U.S. diabetic nephropathy market size was valued at USD 0.79 billion in 2024 and is expected to reach USD 1.13 billion by 2032, growing at a CAGR of 4.66% over the forecast period of 2025-2032.

The North American diabetic nephropathy market is led by the U.S., owing to the higher diabetes burden compared to other countries and improved healthcare infrastructure, along with rapid uptake of novel therapies in the U.S., including SGLT2 inhibitors. Its continuing lead is also supported by solid reimbursement frameworks and good clinical trial activity.

Chronic kidney disease (CKD) affects 14% of the U.S. population aged 20 and older, with 30% of those also having diabetes, according to the Centers for Disease Control and Prevention (CDC). Approximately 30% to 40% of individuals with diabetes mellitus will go on to develop diabetic nephropathy. The global number of people with diabetes is expected to exceed 783 million by 2045, and diabetic complications will take seventh place among the main causes of death in the globe by 2030.

Diabetic Nephropathy Market Dynamics:

Drivers

  • Rising Global Prevalence of Diabetes is Driving the Market Growth

Market growth for diabetic nephropathy is driven mainly by the rising incidence of diabetes, especially type 2 diabetes. Type-2 diabetes makes up about 90–95 % of diabetes, is characterized by insulin resistance, and is closely associated with lifestyle factors such as unhealthy diet, overweight, and reduced physical activity. Estimated to the International Diabetes Federation (IDF), the number of diabetes persons is estimated to increase from 537 million (in 2023) to 783 million (in 2045) globally. The rise in the number of cases leads to a heightened need for early diagnosis, monitoring, and treatment of diabetic nephropathy, fuelling market expansion.

A total of 589 million adults (ages 20–79)—1 in 9 adults globally—were living with diabetes according to the 2025 IDF Diabetes Atlas, and the figure is expected to escalate to 853million by 2050. Disturbingly, 252million stay undiagnosed, which makes the danger of late-stage complications visible on this form of diabetic nephropathy. More than 90% of these cases are due to type-2 diabetes, the principal cause of diabetic kidney disease

  • Advancements in Therapeutic Options are Propelling the Market Expansion

Innovative treatment options, including the emergence of Sodium Glucose Cotransporter 2 (SGLT2) inhibitors (e.g., dapagliflozin (Farxiga) and empagliflozin (Jardiance)), are also driving growth in the diabetic nephropathy market trends. But these drugs have shown more than glucose-lowering effects; they have proven renoprotective and cardioprotective benefits. The inclusion of SGLT-2 inhibitors in international treatment guidelines follows recent clinical trials (e.g., DAPA-CKD and EMPA-KIDNEY) that confirm they slow chronic kidney disease progression in patients with diabetes. These targeted and more effective therapies are expected to not only provide the desired clinical outcomes but also induce wide adoption of these therapies by healthcare providers, which is expected to drive the market growth.

The latest advance is a new class of SGLT inhibitors, sotagliflozin—a dual SGLT1/SGLT2 inhibitor—that has just been reported to reduce heart attacks and strokes by 23% in a chronic kidney disease and diabetes trial involving 10,584 patients reported online in The Lancet Diabetes & Endocrinology. New steroidal SGLT2 inhibitor compounds have also been developed and demonstrate potential in early in vitro investigations. Together with wider regulatory indications and guideline support, these advances increase treatment options and drive the market.                                    

Restraint

  • Stringent Regulatory Requirements are Restraining the Market from Growing

The stringent and elaborate regulatory scenario related to the drug development and approval process is one of the primary restraints in the diabetic nephropathy market analysis. Diabetic nephropathy (DN), the commonest cause of kidney disease, is difficult to treat since there is are interaction among many pathways, including metabolic, inflammatory, and hemodynamic pathways. Approval from regulatory agencies such as the U.S. FDA and EMA requires clinical evidence of both renal and cardiovascular safety in diabetic patients.

That translates to time-consuming and costly phase II and III trial designs, often over multiple years and requiring thousands of patients when it comes to achieving endpoint criteria (delayed progression to ESRD or lower albuminuria output). Moreover, it adds to the regulatory burden by requiring post-marketing surveillance to be done for long-term safety monitoring. These factors increase time-to-market for new drugs, which disincentivizes smaller companies to further invest in this therapeutic area, effectively stifling innovation and reducing the pace of market expansion.

Diabetic Nephropathy Market Segmentation Analysis

By Type

The Type-2 diabetes segment dominated the diabetic nephropathy market share with a 78.4% in 2024 due to its greater global prevalence compared to type-1 diabetes. Type-2 diabetes is one of the main drivers of diabetic kidney disease and is estimated to be responsible for 90–95% of all diabetes cases 22,23. The increasing burden of obesity, sedentary lifestyles, and aging populations—most notably in the U.S., China, and India has also increased the population at risk for nephropathy. Consequently, the needs of this segment in terms of early detection, drug, and renal-protective therapies are moderately increased.

The Type-2 Diabetes segment is projected to be the fastest-growing segment in the forecast period, owing to increasing diagnoses, along with rising disease awareness and growing access to the SGLT2 drug classes, which are treating more and more patients. Moreover, the growing emphasis on early intervention and chronic disease management is driving the mass uptake of nephropathy-based therapies in patients with type 2 diabetes. This growth trajectory is bolstered further by enabling government initiatives, precision medicine advancements, and improved access to healthcare in emerging markets.

By Drugs Class

In 2024, the diabetic nephropathy market was dominated by the angiotensin receptor blockers (ARBs) segment with a 34.2% market share due to their long history as first-line therapy for blood pressure and renal protection in diabetic patients. Angiotensin II receptor blockers (ARBs) such as losartan and irbesartan are frequently prescribed medications with established efficacy in lessening proteinuria and affecting the rate of renal impairment. The broad availability in the health system, low cost, and recommendations in global and disease-specific guidelines are all factors that have helped these drugs become the mainstay within both developed and developing health systems and have contributed to their market leadership.

The sodium glucose cotransporter 2 (SGLT2) inhibitors segment will deliver the fastest growth over the forecast years, due to the large clinical evidence base for renal-protection and cardiovascular advantages, apart from glucose level control, which has been shown for these agents. Beyond diabetes, agents such as dapagliflozin and empagliflozin have also received regulatory approval for the treatment of chronic kidney disease among patients with diabetes, indicating a broadening spectrum of clinical application for these agents. Their use is accelerating due to growing physician preference, greater acceptance in treatment guidelines, and increasing patient awareness, particularly in North America, Europe, and fast-developing Asian markets.

By Distribution Channel

The hospital pharmacy segment dominated the diabetic nephropathy market share with a 56.29% in 2024, owing to the high volume of initial diagnosis and treatment initiation taking place within hospital settings. Diabetic nephropathy generally requires interdisciplinary care involving nephrologists, endocrinologists, and cardiologists, which is generally coordinated through hospitals. In addition, initiation of newer and specialty drugs (e.g., SGLT2 inhibitors or combination therapies) is often performed in clinical practice (e.g., hospital) settings.

The online providers segment is projected to witness the fastest growth during the forecast period, primarily due to the rising use of digital platforms, increasing consumption of e-prescriptions, and the growing requirement for chronic disease drug refills. Since diabetic nephropathy is a long-term drug therapy process, it is possible to keep purchasing drugs at lower prices through online platforms. Moreover, the development of regulations governing the online pharmacy, easier access to the digital payment system, and marketing activities by e-pharmacy platforms are further driving the transition to e-pharmacies, especially in urban centers and developed countries.

Diabetic Nephropathy Market Regional Outlook:

North America dominated the diabetic nephropathy market with a 38.2% market share in 2024 owing to the high prevalence of type-2 diabetes and chronic kidney disease in the region, especially in the U.S. Strong market access is supported by advanced healthcare infrastructure, in-market penetration of innovative therapies such as SGLT2 inhibitors and ARBs, and a favorable reimbursement landscape. Additionally, strong clinical research activity, government support through Medicare and Medicaid programs, and the presence of key pharmaceutical players that develop tests for early diagnosis and efficient management of diseases strengthen North America's dominance in this region.

The Asia Pacific region is growing at the fastest pace with a 5.62% CAGR over the forecast period, due to faster growing diabetic population, urbanization, and lifestyle changes due to these urbanization trends resulting in higher occurrences of obesity and metabolic disorders. India and China are seeing a rise in diabetic nephropathy, which provides a demand for cost-effective therapies (Cheap price) and early screening. Some of the other factors driving the growth of the market include increasing investments in healthcare, access to medical technology, and the availability of generic medicines. The region remains a focus for future growth driven by a perhaps under-appreciated market opportunity and developing healthcare infrastructure.

The diabetic nephropathy market is expanding rapidly in Europe, owing to the increasing incidence of diabetes, rising awareness regarding diabetic kidney complications among the masses, and strong public healthcare systems enabling early diagnosis and treatment. The benefit of major economies within the region adopting advanced therapies such as ACE inhibitors, ARBs, and SGLT2 inhibitors. The region has widespread access to advanced therapies such as ACE inhibitors, ARBs, and SGLT2 inhibitors, particularly within major economies such as Germany, the UK, and France. Market growth in Europe is also steady due to ongoing research projects, the government's implementation of chronic disease management programs, and favorable reimbursement policies.

The diabetic nephropathy market in the Latin American and Middle East & Africa (MEA) regions shows moderate growth due to a slowly rising diabetic population and improved access to appropriate healthcare services. Nevertheless, rapid market growth is constrained by limited awareness, delayed diagnosis, and low adoption of newer therapies such as SGLT2 inhibitors. Overall, in these territories, medicines mostly depend on ordinary medications such as ACE inhibitors and ARBs. Market growth is expected to continue, but at a slower pace, as many of these complexities and challenges are addressed through ongoing healthcare reforms, regulatory shifts, and increasing investments in chronic disease treatment.

Key Players in the Diabetic Nephropathy Market

Diabetic nephropathy market companies are AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck & Co., Reata Pharmaceuticals (Biogen), Novo Nordisk, Sanofi, Johnson & Johnson, and other players.

Recent Developments in the Diabetic Nephropathy Market

  • June 2024 – AstraZeneca's Farxiga (dapagliflozin) was approved by the U.S. Food and Drug Administration (FDA) in paediatric patients with type 2 diabetes (T2D) aged 10 years or older for the improvement of glycaemic control. Approval was granted following the favourable results of the Phase III T2NOW trial. Farxiga was previously approved in the U.S. for adult T2D patients as an adjunct to diet and exercise to control glycaemia.

  • November 2023 – Bayer launched new data for Kerendia (finerenone) showing the dramatic effect of early reduction in albuminuria in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). These results underscore the therapeutic potential of Kerendia for altering the disease course by early treatment.

    Diabetic Nephropathy Market Report Scope:
    Report Attributes Details
    Market Size in 2024 USD 2.71 Billion 
    Market Size by 2032 USD 3.97 Billion 
    CAGR CAGR of 4.98% From 2025 to 2032
    Base Year 2024
    Forecast Period 2025-2032
    Historical Data 2021-2023
    Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Type (Type-1 Diabetes, Type-2 Diabetes)
    • By Drug Class (Angiotensin Receptor Blockers, Diuretics, Renin Inhibitors, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, Others)
    • By Distribution Channel (Drug Stores, Hospital Pharmacy, Retail Pharmacy, Online Providers)
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
    Company Profiles AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck & Co., Reata Pharmaceuticals (Biogen), Novo Nordisk, Sanofi, Johnson & Johnson, and other players.